Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. The company also offers Advantagen, a surgical collagen powder that promotes wound closure and decreases the potential for surgical site infection; and rolled gauze wound care kits. In addition, it provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. Further, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products, as well as retention tapes; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE brand name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, home health agencies, physicians, and health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores. The company was incorporated in 1987 and is based in Oldsmar, Florida.

PROCYON CORP is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.